Arbutus Biopharma Corporation

ABUSNASDAQHealthcare● Active

$4.24

$-0.01(-0.24%)

Market Cap$837559890

P/E Ratio—

52W High$5.1

52W Low$3.04

Avg Volume1.9M

Open$4.30

Beta0.63

Overview

Arbutus Biopharma Corporation (ABUS) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

ABUS · cash on hand · updated Dec 31, 2025

Core cash position

as of Dec 31, 2025

Cash & Short-Term Investments (CCE + ST Investments)

$91.5M▼ -25.4% vs prior year

FY · as of Dec 31, 2025 · Reported in USD

Cash & Cash Equiv. (CCE)

$18.0M

cashAndCashEquivalents

Short-Term Investments

$73.5M

shortTermInvestments

YoY Change vs Prior Year

-25.4%

vs prior fiscal year

Latest Quarter

$95.2M

Q1 2026

Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash vs Debt · Balance Sheet Health

Cash & ST Investments$91.5MCash on Hand

Total Debt$4.2MTotal Debt

Net Cash / Net Debt+$87.3MNet Cash Position

Cash vs Debt Ratio

Cash 96%Arbutus Biopharma Corporation cash as % of market cap: 10.92%% · MCap $1BDebt 4%

Arbutus Biopharma Corporation has a net cash position of $87.3M, holding more cash than debt.

Net Cash = Cash & ST Investments − Total Debt$91.5M − $4.2M = +$87.3M

Cash on hand history

annual cash on hand trend · Cash & Short-Term Investments

YoY Increase

YoY Decrease

Latest Year

ABUS annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

ABUS cash & short-term investments history

DatePeriodCash & ST InvestmentsYoY Change

Dec 31, 2025LatestFY$91.5M-25.4%

Dec 31, 2024FY$122.6M-2.7%

Dec 31, 2023FY$126.0M-14.2%

Dec 31, 2022FY$146.9M-5.4%

Dec 31, 2021FY$155.3M+26.0%

ABUS cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

ABUS vs peers · cash on hand

#CompanyCash & ST Inv.Market CapCash/MCapRelative

UnitedHealth Group Incorporated

Eli Lilly and Company

Arbutus Biopharma CorporationYOU

ABUS

$91.5M$838M10.9%

Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Arbutus Biopharma Corporation (ABUS) cash on hand as of December 31, 2025 is $91.5M, comprising $18.0M in cash and cash equivalents (CCE) plus $73.5M in short-term investments — reported as Arbutus Biopharma Corporation cash and short-term investments on the balance sheet (10-K filing). Also referred to as Arbutus Biopharma Corporation cash reserves or cash position.

Arbutus Biopharma Corporation annual cash on hand history shows decreased -25.4% in 2025: decreased -25.4% in 2025. Arbutus Biopharma Corporation cash reserves in 2025 reflect the company's capital allocation strategy.

Arbutus Biopharma Corporation carries total debt of $4.2M against cash of $91.5M, resulting in a net cash position of +$87.3M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.

Financial statements Free cash flow Net income Revenue Market cap P/E ratio Earnings Price history

Frequently asked questions

ABUS cash on hand · 5 questions

As of December 31, 2025, Arbutus Biopharma Corporation (ABUS) has $91,471,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $18,008,000 in cash and cash equivalents (CCE) plus $73,463,000 in short-term investments. Latest quarter (March 31, 2026): $95,226,000. Data sourced from the annual 10-K filing via FMP.

ABUS cash on handABUS cash reservesABUS cash 2025how much cash does ABUS have

▸ Source: FMP /balance-sheet-statement · US GAAP · Arbutus Biopharma Corporation · Arbutus Biopharma Corporation SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025